MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
5.76
-0.28
-4.56%
After Hours: 5.76 +0.01 +0.17% 16:10 05/29 EDT
OPEN
5.86
PREV CLOSE
6.04
HIGH
6.11
LOW
5.75
VOLUME
35.66K
TURNOVER
--
52 WEEK HIGH
9.82
52 WEEK LOW
3.280
MARKET CAP
98.95M
P/E (TTM)
-5.5776
1D
5D
1M
3M
1Y
5Y
1D
Verrica Pharma CEO Jayson Rieger to present at Jefferies Global Healthcare Conference
PUBT · 1d ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Barchart · 1d ago
Verrica Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 3d ago
Verrica Pharmaceuticals Price Target Announced at $12.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
Benzinga · 3d ago
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
TipRanks · 3d ago
VERRICA PHARMACEUTICALS INC <VRCA.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $12
Reuters · 3d ago
U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy
Reuters · 3d ago
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.